The spontaneous restoration of liver cirrhosis induced by 6 and 9 month CC14 treatment has been studied. The OH-proline content of the liver stroma, the DNA content of the parenchyma, and the Co/DNA ratio were determined. Observations lasted for 4 months after completion of treatment. Cirrhosis developed after 6 month, CC14 administration was reversible in 3--4 months after the discontinuation of treatment; the normal stroma parenchyma ration had gradually normalized. Nine month treatment exhausted the capacity of the stroma for spontaneous recovery and the parenchyma regenerated to a lesser extent. Fibrosis remained practically irreversible 4 months after CC14 administration.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment.
Gastroenterol Hepatol (N Y)
November 2024
Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York.
Alcohol-associated liver disease (ALD) poses a significant global health burden and is a leading cause of liver-related morbidity and mortality. ALD encompasses a spectrum of disease states ranging from asymptomatic steatosis to acute hepatitis and cirrhosis. Alcohol use disorder (AUD) significantly increases the risk of developing ALD, and insight into AUD can provide a more complete understanding of ALD and the patients affected by these interrelated diseases.
View Article and Find Full Text PDFNoninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis.
Gastroenterol Hepatol (N Y)
November 2024
Houston Methodist Hospital, Houston Liver Institute, Houston, Texas.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease, is a major global health issue and a leading cause of chronic liver disease. The prevalence of MASLD is increasing globally, with the disease in some patients progressing to metabolic dysfunction-associated steatohepatitis (MASH), which significantly raises the risk of fibrosis, cirrhosis, and adverse outcomes. Accurate identification of patients with at-risk MASH, defined as MASH with a fibrosis stage of 2 or higher, is critical for timely intervention and management.
View Article and Find Full Text PDFCoinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis.
J Glob Infect Dis
December 2024
Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Introduction: Hepatitis B and C are viral infections causing chronic liver inflammation and, when left untreated, lead to cirrhosis and a risk for hepatocellular carcinoma, the most common type of primary liver cancer with high mortality. The hepatitis B virus-hepatitis C virus (HBV-HCV) coinfection leads to a faster progression to advanced liver diseases and higher hepatocellular carcinoma (HCC) risk than monoinfection. Unlike the relative risk for HCC due to either HBV or HCV, no recent analysis of the risk for HBV-HCV coinfection exists.
View Article and Find Full Text PDFComprehensive profiling of serum microRNAs in normal and non-alcoholic fatty liver disease (NAFLD) patients.
Sci Rep
January 2025
Shaoxing Maternity and Child Health Care Hospital, No. 222 Fenglin East Road, Shaoxing, 312000, Zhejiang, China.
Pediatric non-alcoholic fatty liver disease (NAFLD) is emerging as a worldwide health concern with the potential to advance to cirrhosis and liver cancer. NAFLD can also directly contribute to heart problems through inflammation and insulin resistance, even in individuals without other risk factors. The pathological mechanisms of NAFLD are linked to functional differences of miRNAs in different biological environments.
View Article and Find Full Text PDFRoles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential.
Med Oncol
January 2025
Department of Hepatobiliary Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a highly aggressive malignancy with limited viable therapeutic options. For early HCC, resection surgery is currently the most effective treatment. However, in advanced stages, resection alone does not sufficiently address the disease, so finding a method with a better prognosis is necessary.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!